Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014-2015.

Morrissey I, Magnet S, Hawser S, Shapiro S, Knechtle P.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00514-19. doi: 10.1128/AAC.00514-19. Print 2019 Jul.

2.

Kinetic mechanism of Enterococcus faeciumd-aspartate ligase.

Škedelj V, Fonović UP, Molek P, Magnet S, Mainardi JL, Blanot D, Gobec S, Stojan J, Zega A.

Biochimie. 2019 Mar;158:217-223. doi: 10.1016/j.biochi.2019.01.012. Epub 2019 Jan 22.

PMID:
30682389
3.

In Vitro Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections.

Noviello S, Magnet S, Hawser S, Huang DB.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02239-18. doi: 10.1128/AAC.02239-18. Print 2019 Apr.

PMID:
30642922
4.

Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe.

Huang DB, Magnet S, De Angelis S, Holland TL, File TM Jr, Dryden M, Corey GR, Torres A, Wilcox MH.

Diagn Microbiol Infect Dis. 2019 Feb;93(2):154-158. doi: 10.1016/j.diagmicrobio.2018.09.002. Epub 2018 Sep 10.

PMID:
30266399
5.

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.

Karlowsky JA, Lob SH, Kazmierczak KM, Hawser SP, Magnet S, Young K, Motyl MR, Sahm DF.

J Antimicrob Chemother. 2018 Jul 1;73(7):1872-1879. doi: 10.1093/jac/dky107.

PMID:
29659861
6.

Discovery of a Novel Metallo-β-Lactamase Inhibitor That Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae.

Everett M, Sprynski N, Coelho A, Castandet J, Bayet M, Bougnon J, Lozano C, Davies DT, Leiris S, Zalacain M, Morrissey I, Magnet S, Holden K, Warn P, De Luca F, Docquier JD, Lemonnier M.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00074-18. doi: 10.1128/AAC.00074-18. Print 2018 May.

7.

Activity of RX-P873, a novel pyrrolocytosine, against Gram-negative bacteria.

Morrissey I, Magnet S, Genet E, Jeandey P, Marra A, Hawser S, Duffy E.

Int J Antimicrob Agents. 2015 Sep;46(3):352-4. doi: 10.1016/j.ijantimicag.2015.06.001. Epub 2015 Jun 19. No abstract available.

PMID:
26159867
8.

Structural studies suggest a peptidoglycan hydrolase function for the Mycobacterium tuberculosis Tat-secreted protein Rv2525c.

Bellinzoni M, Haouz A, Miras I, Magnet S, André-Leroux G, Mukherjee R, Shepard W, Cole ST, Alzari PM.

J Struct Biol. 2014 Nov;188(2):156-64. doi: 10.1016/j.jsb.2014.09.003. Epub 2014 Sep 24.

PMID:
25260828
9.

Discovery of the first inhibitors of bacterial enzyme D-aspartate ligase from Enterococcus faecium (Aslfm).

Škedelj V, Perdih A, Brvar M, Kroflič A, Dubbée V, Savage V, O'Neill AJ, Solmajer T, Bešter-Rogač M, Blanot D, Hugonnet JE, Magnet S, Arthur M, Mainardi JL, Stojan J, Zega A.

Eur J Med Chem. 2013 Sep;67:208-20. doi: 10.1016/j.ejmech.2013.06.017. Epub 2013 Jun 28.

PMID:
23867605
10.

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid.

Hartkoorn RC, Sala C, Neres J, Pojer F, Magnet S, Mukherjee R, Uplekar S, Boy-Röttger S, Altmann KH, Cole ST.

EMBO Mol Med. 2012 Oct;4(10):1032-42. doi: 10.1002/emmm.201201689. Epub 2012 Sep 17.

11.

Colicin M hydrolyses branched lipids II from Gram-positive bacteria.

Patin D, Barreteau H, Auger G, Magnet S, Crouvoisier M, Bouhss A, Touzé T, Arthur M, Mengin-Lecreulx D, Blanot D.

Biochimie. 2012 Apr;94(4):985-90. doi: 10.1016/j.biochi.2011.12.019. Epub 2011 Dec 26.

PMID:
22210388
12.

Leads for antitubercular compounds from kinase inhibitor library screens.

Magnet S, Hartkoorn RC, Székely R, Pató J, Triccas JA, Schneider P, Szántai-Kis C, Orfi L, Chambon M, Banfi D, Bueno M, Turcatti G, Kéri G, Cole ST.

Tuberculosis (Edinb). 2010 Nov;90(6):354-60. doi: 10.1016/j.tube.2010.09.001. Epub 2010 Oct 8.

PMID:
20934382
13.

Sigma factor F does not prevent rifampin inhibition of RNA polymerase or cause rifampin tolerance in Mycobacterium tuberculosis.

Hartkoorn RC, Sala C, Magnet SJ, Chen JM, Pojer F, Cole ST.

J Bacteriol. 2010 Oct;192(20):5472-9. doi: 10.1128/JB.00687-10. Epub 2010 Aug 20.

14.

Quantitative high-performance liquid chromatography analysis of the pool levels of undecaprenyl phosphate and its derivatives in bacterial membranes.

Barreteau H, Magnet S, El Ghachi M, Touzé T, Arthur M, Mengin-Lecreulx D, Blanot D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15;877(3):213-20. doi: 10.1016/j.jchromb.2008.12.010. Epub 2008 Dec 11.

PMID:
19110475
15.

Identification of the L,D-transpeptidases for peptidoglycan cross-linking in Escherichia coli.

Magnet S, Dubost L, Marie A, Arthur M, Gutmann L.

J Bacteriol. 2008 Jul;190(13):4782-5. doi: 10.1128/JB.00025-08. Epub 2008 May 2.

16.

Covalent attachment of proteins to peptidoglycan.

Dramsi S, Magnet S, Davison S, Arthur M.

FEMS Microbiol Rev. 2008 Mar;32(2):307-20. doi: 10.1111/j.1574-6976.2008.00102.x. Epub 2008 Feb 11. Review.

17.

AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.

Damier-Piolle L, Magnet S, Brémont S, Lambert T, Courvalin P.

Antimicrob Agents Chemother. 2008 Feb;52(2):557-62. Epub 2007 Dec 17.

18.

Identification of the L,D-transpeptidases responsible for attachment of the Braun lipoprotein to Escherichia coli peptidoglycan.

Magnet S, Bellais S, Dubost L, Fourgeaud M, Mainardi JL, Petit-Frère S, Marie A, Mengin-Lecreulx D, Arthur M, Gutmann L.

J Bacteriol. 2007 May;189(10):3927-31. Epub 2007 Mar 16.

19.

Specificity of L,D-transpeptidases from gram-positive bacteria producing different peptidoglycan chemotypes.

Magnet S, Arbeloa A, Mainardi JL, Hugonnet JE, Fourgeaud M, Dubost L, Marie A, Delfosse V, Mayer C, Rice LB, Arthur M.

J Biol Chem. 2007 May 4;282(18):13151-9. Epub 2007 Feb 20.

20.

The Enterococcus hirae Mur-2 enzyme displays N-acetylglucosaminidase activity.

Eckert C, Magnet S, Mesnage S.

FEBS Lett. 2007 Feb 20;581(4):693-6. Epub 2007 Jan 22.

21.

Molecular insights into aminoglycoside action and resistance.

Magnet S, Blanchard JS.

Chem Rev. 2005 Feb;105(2):477-98. Review. No abstract available.

PMID:
15700953
22.

Structure and functions of the GNAT superfamily of acetyltransferases.

Vetting MW, S de Carvalho LP, Yu M, Hegde SS, Magnet S, Roderick SL, Blanchard JS.

Arch Biochem Biophys. 2005 Jan 1;433(1):212-26. Review.

PMID:
15581578
23.

Nitroxide-mediated controlled free-radical emulsion polymerization of styrene and n-butyl acrylate with a water-soluble alkoxyamine as initiator.

Nicolas J, Charleux B, Guerret O, Magnet S.

Angew Chem Int Ed Engl. 2004 Nov 19;43(45):6186-9. No abstract available.

PMID:
15549749
24.

A bacterial acetyltransferase capable of regioselective N-acetylation of antibiotics and histones.

Vetting MW, Magnet S, Nieves E, Roderick SL, Blanchard JS.

Chem Biol. 2004 Apr;11(4):565-73.

25.

Aminoglycoside microarrays to study antibiotic resistance.

Disney MD, Magnet S, Blanchard JS, Seeberger PH.

Angew Chem Int Ed Engl. 2004 Mar 12;43(12):1591-4. No abstract available.

PMID:
15022242
26.

Mechanistic and kinetic study of the ATP-dependent DNA ligase of Neisseria meningitidis.

Magnet S, Blanchard JS.

Biochemistry. 2004 Jan 27;43(3):710-7.

PMID:
14730975
27.

What can structure tell us about in vivo function? The case of aminoglycoside-resistance genes.

Vetting M, Roderick SL, Hegde S, Magnet S, Blanchard JS.

Biochem Soc Trans. 2003 Jun;31(Pt 3):520-2. Review.

PMID:
12773148
28.

Aminoglycoside resistance resulting from tight drug binding to an altered aminoglycoside acetyltransferase.

Magnet S, Smith TA, Zheng R, Nordmann P, Blanchard JS.

Antimicrob Agents Chemother. 2003 May;47(5):1577-83.

29.
30.

Kinetic and mutagenic characterization of the chromosomally encoded Salmonella enterica AAC(6')-Iy aminoglycoside N-acetyltransferase.

Magnet S, Lambert T, Courvalin P, Blanchard JS.

Biochemistry. 2001 Mar 27;40(12):3700-9.

PMID:
11297438
32.

Legislating for an informed consent to medical treatment by competent adults.

Magnet SR.

McGill Law J. 1981;26(4):1056-67. No abstract available.

PMID:
11650589

Supplemental Content

Loading ...
Support Center